NAAA
CORT icon

New Age Alpha Advisors’s Corcept Therapeutics CORT Stock Holding History

New Age Alpha Advisors’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-4,453
Closed -$370K – 793
2025
Q3 		$370K Sell
4,453
-114
-2% -$8.25K 0.02% 532
2025
Q2 		$335K Sell
4,567
-208
-4% -$15.1K 0.01% 535
2025
Q1 		$545K Buy
4,775
+1,255
+36% +$76.4K 0.02% 495
2024
Q4 		$177K Buy
+3,520
New +$184K 0.01% 675

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

New Age Alpha Advisors's CORT Position: Q4 2025 in Review

New Age Alpha Advisors sold out of Corcept Therapeutics (CORT) in Q4 2025, closing a stake of 4,453 shares — an estimated $370K sold.

New Age Alpha Advisors first reported a position in CORT in Q4 2024 and held it in 4 quarters. The position peaked at $545K in Q1 2025. 389 funds tracked by Wall St. Rank hold CORT as of Q4 2025.

  • New Age Alpha Advisors reported no remaining Corcept Therapeutics position as of Q4 2025 after selling out during the quarter.
  • New Age Alpha Advisors sold 4,453 Corcept Therapeutics shares in Q4 2025, an estimated $370K.
  • New Age Alpha Advisors first reported a position in Corcept Therapeutics in Q4 2024 and held it in 4 quarters.
  • New Age Alpha Advisors's Corcept Therapeutics position peaked at $545K in Q1 2025.
  • 389 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2025.

Based on New Age Alpha Advisors's 13F filing for Q4 2025, filed 9 Feb 2026.